Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020.
Benzodiazepines
Gabapentinoids
Gender
Opioid use disorder
Prescription opioids
Prison prescribing
Z-drugs
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
06 10 2023
06 10 2023
Historique:
received:
31
05
2023
accepted:
15
09
2023
medline:
1
11
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Pharmacotherapy is essential for the delivery of an equivalent standard of care in prison. Prescribing can be challenging due to the complex health needs of prisoners and the risk of misuse of prescription drugs. This study examines prescribing trends for drugs with potential for misuse (opioids, benzodiazepines, Z-drugs, and gabapentinoids) in Irish prisons and whether trends vary by gender and history of opioid use disorder (OUD). A repeated cross-sectional study between 2012 and 2020 using electronic prescribing records from the Irish Prison Services, covering all prisons in the Republic of Ireland was carried out. Prescribing rates per 1,000 prison population were calculated. Negative binomial (presenting adjusted rate ratios (ARR) per year and 95% confidence intervals) and joinpoint regressions were used to estimate time trends adjusting for gender, and for gender specific analyses of prescribing trends over time by history of OUD. A total of 10,371 individuals were prescribed opioid agonist treatment (OAT), opioids, benzodiazepines, Z-drugs or gabapentinoids during study period. History of OUD was higher in women, with a median rate of 597 per 1,000 female prisoners, compared to 161 per 1,000 male prisoners. Prescribing time trends, adjusted for gender, showed prescribing rates decreased over time for prescription opioids (ARR 0.82, 95% CI 0.80-0.85), benzodiazepines (ARR 0.99, 95% CI 0.98-0.999), Z-drugs (ARR 0.90, 95% CI 0.88-0.92), but increased for gabapentinoids (ARR 1.07, 95% CI 1.05-1.08). However, prescribing rates declined for each drug class between 2019 and 2020. Women were significantly more likely to be prescribed benzodiazepines, Z-drugs and gabapentinoids relative to men. Gender-specific analyses found that men with OUD, relative to men without, were more likely to be prescribed benzodiazepines (ARR 1.49, 95% CI 1.41-1.58), Z-drugs (ARR 10.09, 95% CI 9.0-11.31), gabapentinoids (ARR 2.81, 95% CI 2.66-2.97). For women, history of OUD was associated with reduced gabapentinoid prescribing (ARR 0.33, 95% CI 0.28-0.39). While the observed reductions in prescription opioid, benzodiazepine and Z-drug prescribing is consistent with guidance for safe prescribing in prisons, the increase in gabapentinoid (primarily pregabalin) prescribing and the high level of prescribing to women is concerning. Our findings suggest targeted interventions may be needed to address prescribing in women, and men with a history of OUD.
Sections du résumé
BACKGROUND
Pharmacotherapy is essential for the delivery of an equivalent standard of care in prison. Prescribing can be challenging due to the complex health needs of prisoners and the risk of misuse of prescription drugs. This study examines prescribing trends for drugs with potential for misuse (opioids, benzodiazepines, Z-drugs, and gabapentinoids) in Irish prisons and whether trends vary by gender and history of opioid use disorder (OUD).
METHODS
A repeated cross-sectional study between 2012 and 2020 using electronic prescribing records from the Irish Prison Services, covering all prisons in the Republic of Ireland was carried out. Prescribing rates per 1,000 prison population were calculated. Negative binomial (presenting adjusted rate ratios (ARR) per year and 95% confidence intervals) and joinpoint regressions were used to estimate time trends adjusting for gender, and for gender specific analyses of prescribing trends over time by history of OUD.
RESULTS
A total of 10,371 individuals were prescribed opioid agonist treatment (OAT), opioids, benzodiazepines, Z-drugs or gabapentinoids during study period. History of OUD was higher in women, with a median rate of 597 per 1,000 female prisoners, compared to 161 per 1,000 male prisoners. Prescribing time trends, adjusted for gender, showed prescribing rates decreased over time for prescription opioids (ARR 0.82, 95% CI 0.80-0.85), benzodiazepines (ARR 0.99, 95% CI 0.98-0.999), Z-drugs (ARR 0.90, 95% CI 0.88-0.92), but increased for gabapentinoids (ARR 1.07, 95% CI 1.05-1.08). However, prescribing rates declined for each drug class between 2019 and 2020. Women were significantly more likely to be prescribed benzodiazepines, Z-drugs and gabapentinoids relative to men. Gender-specific analyses found that men with OUD, relative to men without, were more likely to be prescribed benzodiazepines (ARR 1.49, 95% CI 1.41-1.58), Z-drugs (ARR 10.09, 95% CI 9.0-11.31), gabapentinoids (ARR 2.81, 95% CI 2.66-2.97). For women, history of OUD was associated with reduced gabapentinoid prescribing (ARR 0.33, 95% CI 0.28-0.39).
CONCLUSIONS
While the observed reductions in prescription opioid, benzodiazepine and Z-drug prescribing is consistent with guidance for safe prescribing in prisons, the increase in gabapentinoid (primarily pregabalin) prescribing and the high level of prescribing to women is concerning. Our findings suggest targeted interventions may be needed to address prescribing in women, and men with a history of OUD.
Identifiants
pubmed: 37803285
doi: 10.1186/s12888-023-05195-9
pii: 10.1186/s12888-023-05195-9
pmc: PMC10559424
doi:
Substances chimiques
Analgesics, Opioid
0
Prescription Drugs
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
725Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Cremers S, Wright DFB. Nonmedical use of prescription drugs. Br J Clin Pharmacol. 2021;87(4):1635–6.
pubmed: 33710669
Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1(3):255–62.
pubmed: 19630724
Hockenhull J, Black JC, Haynes CM, Rockhill K, Dargan PI, Dart RC, et al. Nonmedical use of benzodiazepines and Z-drugs in the UK. Br J Clin Pharmacol. 2021;87(4):1676–83.
pubmed: 32472941
Wood DM, Dargan PI. Regional, national and international datasets: how they improve our understanding of the acute harms associated with prescription medicine misuse. Br J Clin Pharmacol. 2021;87(4):1654–9.
pubmed: 33118204
Marsden J, White M, Annand F, Burkinshaw P, Carville S, Eastwood B, et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry. 2019;6(11):935–50.
pubmed: 31588045
pmcid: 7029276
Zarocostas J. Misuse of prescription drugs could soon exceed that of illicit narcotics, UN panel warns. BMJ. 2007;334(7591):444–4.
pubmed: 17332555
pmcid: 1808161
Global UNODC, SMART Update [Internet]. 2017 Sep [cited 2023 Apr 27]. Report No.: Volume 18. Available from: https://www.unodc.org/documents/scientific/Global_SMART_Update_2017_Vol_18.pdf .
UNODC. World Drug Report 2018 [Internet]. 2018 [cited 2023 Apr 27]. Available from: https://www.unodc.org/wdr2018/ .
Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967–71.
pubmed: 24067791
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
pubmed: 28292769
pmcid: 5421443
Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337–52.
pubmed: 31496087
pmcid: 6732697
Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-Drug abuse and dependence: an examination of reports to the european Medicines Agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22(4):270–7.
pubmed: 30722037
pmcid: 6441128
Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of Pregabalin and Gabapentin: a systematic review update. Drugs. 2021;81(1):125–56.
pubmed: 33215352
Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.
pubmed: 27265421
pmcid: 5573873
Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580–9.
pubmed: 28493329
pmcid: 5635829
Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725–39.
pubmed: 28543749
pmcid: 5589068
Gulati G, Keating N, O’Neill A, Delaunois I, Meagher D, Dunne CP. The prevalence of major mental illness, substance misuse and homelessness in irish prisoners: systematic review and meta-analyses. Ir J Psychol Med. 2019;36(1):35–45.
pubmed: 30931873
Hassan L, Senior J, Webb RT, Frisher M, Tully MP, While D, et al. Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England. BMC Psychiatry. 2016;16(1):346.
pubmed: 27724879
pmcid: 5057241
Abuzour AS, Magola-Makina E, Dunlop J, O’Brien A, Khawagi WY, Ashcroft DM, et al. Implementing prescribing safety indicators in prisons: a mixed methods study. Br J Clin Pharmacol. 2022;88(4):1866–84.
pubmed: 34625991
Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122–31.
pubmed: 28086177
Rutherford M, Duggan S. Meeting complex health needs in prisons. Public Health. 2009;123(6):415–8.
pubmed: 19482321
Royal College of General Practitioners. Safer prescribing in prisons - Guidance for clinicians. Safer Prescribing in Prisons. Report No.: Second edition: Royal College of General Practitioners; 2019. p. 104.
European Monitoring Centre for Drugs and Drug Addiction. Prison and drugs in Europe: current and future challenges. [Internet]. LU: Publications Office. ; 2022 [cited 2023 Feb 20]. Available from: https://data.europa.eu/doi/10.2810/420042 .
Durand L, Boland F, O’Driscoll D, Bennett K, Barry J, Keenan E, et al. Factors associated with early and later dropout from methadone maintenance treatment in specialist addiction clinics: a six-year cohort study using proportional hazards frailty models for recurrent treatment episodes. Drug Alcohol Depend. 2021;219:108466.
pubmed: 33421801
Vold JH, Skurtveit S, Aas C, Chalabianloo F, Kloster PS, Johansson KA, et al. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC Health Serv Res. 2020;20(1):352.
pubmed: 32334602
pmcid: 7183604
Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64.
pubmed: 28315808
Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Reutfors J, et al. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Open. 2020;10(8):e036860.
pubmed: 32771988
pmcid: 7418685
Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1):8–18.
pubmed: 22857878
pmcid: 3454351
Durand L, O’Driscoll D, Boland F, Keenan E, Ryan BK, Barry J, et al. Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study. Addiction. 2020;115(10):1867–77.
pubmed: 32034837
pmcid: 7540578
Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965.
pubmed: 31770388
pmcid: 6879111
Irish Prison Service. Annual Report [Internet]. Irish Prison Service; 2020 [cited 2023 Feb 8]. Available from: https://www.irishprisons.ie/wp-content/uploads/documents_pdf/IPS-Annual-Report-web-FINAL.pdf .
Ireland. : national report for 2021 - prison. [Internet]. Dublin: Health Research Board; 2022 Feb [cited 2023 Feb 2]. Available from: https://www.drugsandalcohol.ie/25265/ .
Cousins G, Durand L, O’Kane A, Tierney J, Maguire R, Stokes S, et al. Prescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020. BMJ Open. 2023;13(3):e069665.
pubmed: 36863742
pmcid: 9990618
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–35.
pubmed: 18049195
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using Observational routinely-collected health data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885.
pubmed: 26440803
pmcid: 4595218
Anatomical Therapeutic Chemical (ATC). Classification [Internet]. [cited 2023 Apr 27]. Available from: https://www.who.int/tools/atc-ddd-toolkit/atc-classification .
Joinpoint Regression Program, version 4.9.1.0 April 2022. Statistical methodology and Applications Branch. Surveillance Research Program, National Cancer Institute.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51: (correction: 2001;20:655).
SAS Enterprise Guide v7.1. Cary: SAS Institute Inc.
Norris BA, Smith A, Doran S, Barry M. Trends in strong opioid prescribing in Ireland: a repeated cross-sectional analysis of a national pharmacy claims database between 2010 and 2019. Pharmacoepidemiol Drug Saf. 2021;30(8):1003–11.
pubmed: 33840133
Cadogan CA, Ryan C, Cahir C, Bradley CP, Bennett K. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol. 2018;84(6):1354–63.
pubmed: 29488252
pmcid: 5980334
Lynn E. Has an increase in the dispensing of pregabalin influenced poisoning deaths in Ireland? Drugnet Irel. 2019;Issue 71, Autumn 2019:15–7. Available from: https://www.drugsandalcohol.ie/31455/1/HRB_Drugnet_Issue_71.pdf .
Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken: Wiley; 2019.
Annaheim B, Bretschneider W, Handtke V, Belardi A, Elger BS. Prescription of pain medication in prisons: a comparative analysis of younger and older male prisoners. Pharmacoepidemiol Drug Saf. 2018;27(9):987–94.
pubmed: 29926998
Prison statistics [Internet]. [cited 2023 Jan 9]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Prison_statistics .
Hanrahan MT, Millar S, Phillips KP, Reed TE, Mongan D, Perry IJ. Problematic opioid use in Ireland, 2015–2019. [Internet]. Dublin: Health Research Board; 2022 Oct [cited 2023 Apr 26]. Available from: https://www.drugsandalcohol.ie/35856/ .
Review of Drug and Alcohol Treatment Services for Adult Offenders in Prison and in the Community [Internet]. 2016 [cited 2023 Apr 22]. Available from: https://ipo.gov.ie/en/JELR/PS_IPS_Probation_Review_of_treatment_for_offenders.pdf/Files/PS_IPS_Probation_Review_of_treatment_for_offenders.pdf .
Durand L, Keenan E, Boland F, Harnedy N, Delargy Í, Scully M, et al. Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study. Int J Drug Policy. 2022;106:103768.
pubmed: 35738029
pmcid: 9212711
Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the Opioid Crisis in North America and Beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555–604.
pubmed: 35122753
pmcid: 9261968
Chen TC, Chen LC, Knaggs RD. A 15-year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom. Pharmacoepidemiol Drug Saf. 2018;27(5):487–94.
pubmed: 28944519
Croft M, Mayhew R. Prevalence of chronic non-cancer pain in a UK prison environment. Br J Pain. 2015;9(2):96–108.
pubmed: 26516564
pmcid: 4616963
Tyler N, Miles HL, Karadag B, Rogers G. An updated picture of the mental health needs of male and female prisoners in the UK: prevalence, comorbidity, and gender differences. Soc Psychiatry Psychiatr Epidemiol. 2019;54(9):1143–52.
pubmed: 30903239
Fazel S, Baillargeon J. The health of prisoners. The Lancet. 2011;377(9769):956–65.
Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry [Internet]. 2021 Jun 2 [cited 2021 Jul 22]; https://doi.org/10.1001/jamapsychiatry.2021.0976 .
Strang J. Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths. Addiction. 2015;110(Suppl 2):27–35.
pubmed: 26042565
Pelizza L, Maestri D, Paulillo G, Pellegrini P. Prevalence and appropriateness of antipsychotic prescribing in an italian prison: is everything Always really overprescribed? J Clin Psychopharmacol. 2022;42(1):31.
pubmed: 34928558